Remnant cholesterol as a causal risk factor for ischemic heart disease.
about
Triglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseTriglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and EuropeanHypertriglyceridemia and Cardiovascular Diseases: RevisitedResidual macrovascular risk in 2013: what have we learned?Mendelian randomization studies: a review of the approaches used and the quality of reportingMechanisms of Comorbidities Associated With the Metabolic Syndrome: Insights from the JCR:LA-cp Corpulent Rat StrainCommon variants associated with plasma triglycerides and risk for coronary artery diseaseOlive oil and postprandial hyperlipidemia: implications for atherosclerosis and metabolic syndrome.Hypertriglyceridemia: the importance of identifying patients at risk.Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.Mendelian randomization of blood lipids for coronary heart disease.Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventionPatients with type 1 diabetes show signs of vascular dysfunction in response to multiple high-fat meals.Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant CholesterolRare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity.Metabolic syndrome and its predictors in an urban population in Kenya: A cross sectional study.The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglyceridesMonogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts.Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.APOC3: Triglycerides do matter.The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney diseaseNovel method for reducing plasma cholesterol: a ligand replacement therapy.How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?Triglycerides on the rise: should we swap seats on the seesaw?Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by StatinsIdentifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State.Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case-control and meta-analysis study.Effects of a Plant Sterol or Stanol Enriched Mixed Meal on Postprandial Lipid Metabolism in Healthy Subjects.Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients.How an artery heals.Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki diseaseRemnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry.Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placeboSurprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.
P2860
Q26745946-99F472C2-B513-4E70-8E37-0294F1A44679Q26746279-77AD7476-266C-4C65-B3CB-556AC4121867Q26749306-C971CFFD-3EAA-47FA-88B2-3EB61A96331CQ26750954-DB753119-EA65-4D87-9EB7-54B5DCFD584CQ26996039-6B618643-6BFE-4B83-BC75-72D4E4407F38Q26999349-4A546CCC-81B8-431F-9831-052575A4D4A0Q28066227-1D522043-6D81-479B-87C7-82BEABF5F546Q28659915-E9440F69-89FD-4E29-A0CD-4DC68217B130Q30240705-EBB7C4BA-E7D8-4FC3-8589-DD8A532434BFQ30244825-397C3E76-82C1-4769-A636-52429486428CQ30301147-ACF2B5FF-3A7C-4651-9738-FF34E904699AQ30407506-3C5FD7BF-C6D5-4F72-9551-35B442E02527Q33646780-969762CD-2B48-4A45-8B31-B08C0BA914DEQ33776194-90572867-9344-450C-9EB4-3F6FA1267DEBQ33780134-522CE060-6511-4151-97DE-67438022EC18Q33792579-D3DE7AAC-9F98-4961-BF13-5380AFD4B7B5Q33848771-15851EC3-DDF2-4F3F-A850-29C210CEB032Q33854345-8C4557B1-2930-48EE-9883-375166C21183Q33869151-1C68DDF6-4B0D-4305-B5F8-5C91DF150EF8Q34359967-C13E90BF-C811-45E9-961F-466838F1EA3FQ34406987-926990B6-B3F8-4EDE-9E6C-C732E9267A70Q34441411-64D8EF63-DB06-4182-A212-54C380B53001Q34548284-690DFB7A-B355-4244-9D26-D75BC67AE895Q34551430-9D27EA44-E09B-40E5-82D5-867CB2E6A748Q34687470-D860FA9D-D7FC-4B77-826D-70EC6C512EC9Q35156608-9B425FE8-A198-4B87-90BD-0D57046C6455Q35530832-576AA3F2-2E9D-4E74-9F43-F82A9282C6DDQ35558371-963DA701-AF06-4713-8306-FA9C5458448CQ35738372-58B587D9-63A7-4777-B591-92FEA8A00ACAQ35753514-68333B49-2AF5-46F5-A278-07B0556B3A37Q35785415-1D94DDC5-BCF3-4258-B4FD-B98C995BBDEFQ36011783-D9575DCE-CF84-4F9C-BAA5-27D56BAB72DDQ36073931-2E9A6092-6822-4F3E-80BF-590FB5306C04Q36127911-45469543-E8F3-446E-A1F4-DCA4A5E375F4Q36156630-D87EA1C4-6D48-47CA-ABA9-2C1DDD51E612Q36329387-ECDEC0F0-D15C-49BF-93AF-CBB5F384CEAFQ36416679-49B49656-9096-4AED-A38B-A68CEA49E24CQ36470182-F2CC2C40-8F71-4F87-AC57-E1E8B11C74D8Q36577724-647A2849-B425-4BF6-BE2C-978982A4D397Q36602779-BA3D122E-F9D1-4D59-8EBF-D200BB9B9A9C
P2860
Remnant cholesterol as a causal risk factor for ischemic heart disease.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@ast
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@en
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@nl
type
label
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@ast
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@en
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@nl
prefLabel
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@ast
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@en
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@nl
P2093
P50
P1476
Remnant cholesterol as a causal risk factor for ischemic heart disease.
@en
P2093
Anders B Jørgensen
Anette Varbo
Ruth Frikke-Schmidt
P304
P356
10.1016/J.JACC.2012.08.1026
P407
P577
2012-12-19T00:00:00Z